MABC171
Anti-Isocitrate Dehydrogenase 1 (IDH1)-R132H Antibody, clone HMab-1
clone HMab-1, from mouse
Synonym(s):
Isocitrate dehydrogenase [NADP] cytoplasmic, IDH, Cytosolic NADP-isocitrate dehydrogenase, IDP, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
HMab-1, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... IDH1(3417)
General description
Isocitrate dehydrogenase 1 (IDH1) is a 46 kDa NADP-dependent enzyme, which catalyzes the decarboxylation of isocitrate into α-ketoglutarate. IDH1 may also play a role in the prevention of oxidative damage, and the shuttling of proteins to peroxisomes. It is widely reported that mutations in IDH1 result in various types of glioma.
Specificity
This antibody is specific for the R132H mutation of Isocitrate Dehydrogenase 1 (IDH1).
Immunogen
KLH-conjugated linear peptide corresponding to human Isocitrate Dehydrogenase 1 (IDH1).
Application
Detect Isocitrate Dehydrogenase 1 (IDH1)-R132H using this Anti-Isocitrate Dehydrogenase 1 (IDH1)-R132H Antibody, clone HMab-1 validated for use in Western Blotting, IHC, ICC.
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Apoptosis - Additional
Western Blot Analysis: A representative lot of this antibody detected Isocitrate Dehydrogenase 1 (IDH1)-R132S in a panel of wild-type and mutated recombinant IDH1 proteins.
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Isocitrate Dehydrogenase 1 (IDH1)-R132S in anaplastic and diffuse astrocytoma tissues and in primary glioblastoma tissues (Kato, Y., et al. (2009). Biochem Biophys Res Commun. 390(3):547-51.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Isocitrate Dehydrogenase 1 (IDH1)-R132S in transfected glioblastoma and transfected LN229 cells (Kaneko, M. K., et al. (2011). Biochem Biophys Res Commun. 406(4):608-613.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Isocitrate Dehydrogenase 1 (IDH1)-R132S in anaplastic and diffuse astrocytoma tissues and in primary glioblastoma tissues (Kato, Y., et al. (2009). Biochem Biophys Res Commun. 390(3):547-51.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Isocitrate Dehydrogenase 1 (IDH1)-R132S in transfected glioblastoma and transfected LN229 cells (Kaneko, M. K., et al. (2011). Biochem Biophys Res Commun. 406(4):608-613.).
Quality
Evaluated by Western Blot in MBP-tagged recombinant Isocitrate Dehydrogenase 1 (IDH1).
Western Blot Analysis: A 1:500 dilution of this antibody detected MBP tagged recombinant Isocitrate Dehydrogenase 1 (IDH1) in WB.
Western Blot Analysis: A 1:500 dilution of this antibody detected MBP tagged recombinant Isocitrate Dehydrogenase 1 (IDH1) in WB.
Target description
~90 kDa observed. The calculated molecular weight of Isocitrate Dehydrogenase 1 (IDH1) is 47 kDa However, a Western Blot was performed using an MBP-tagged recombinant Isocitrate Dehydrogenase 1 (IDH1). Because MBP has a molecular weight of ~42 kDa, a band was observed at ~90 kDa
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
MBP tagged recombinant Isocitrate Dehydrogenase 1 (IDH1)
MBP tagged recombinant Isocitrate Dehydrogenase 1 (IDH1)
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Victor Ruiz-Rodado et al.
Molecular oncology, 16(9), 1777-1794 (2021-12-03)
Nutritional intervention is becoming more prevalent as adjuvant therapy for many cancers in view of the tumor dependence on external sources for some nutrients. However, little is known about the mechanisms that make cancer cells require certain nutrients from the
Roberta Soares Faccion et al.
Cellular oncology (Dordrecht), 41(2), 141-157 (2018-01-28)
Diffuse astrocytic tumors are the most frequently occurring primary central nervous system (CNS) tumors. Their histological sub-classification into diffuse astrocytoma (DA), anaplastic astrocytoma (AA) and glioblastoma (GB) is challenging and the available prognostic factors are limited to age and tumor
Fatih Erdi et al.
Turkish neurosurgery, 28(1), 7-12 (2017-03-28)
To evaluate and compare the expression of thioredoxin reductase 1 (TrxR1) in primary and secondary glioblastoma samples. Surgically resected human glioblastoma samples from 40 patients who underwent surgery at our institution were extracted from their histopathological specimens and divided into
Natalia J Martinez et al.
Scientific reports, 8(1), 9472-9472 (2018-06-23)
Assessment of the interactions between a drug and its protein target in a physiologically relevant cellular environment constitutes a major challenge in the pre-clinical drug discovery space. The Cellular Thermal Shift Assay (CETSA) enables such an assessment by quantifying the
Irati Hervás-Corpión et al.
Cancers, 13(21) (2021-11-14)
Glioblastoma (GB) is the most aggressive form of glioma and is characterized by poor prognosis and high recurrence despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB with potential diagnosis utility, we combined the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service